Page last updated: 2024-09-02

kt 6149 and Adenocarcinoma

kt 6149 has been researched along with Adenocarcinoma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19902 (40.00)18.7374
1990's3 (60.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Dumortier, A; Evene, E; Joossens, E; Koier, I; Provè, A; Schrijvers, D1
Ashizawa, T; Gomi, K; Hirata, T; Okabe, M1
Asami, N; Inaba, M; Morimoto, M; Sudo, Y; Tsuruo, T1
Abe, O; Arisawa, Y; Inada, T; Inoue, S; Ishibiki, K; Kodaira, S; Kubota, T; Kuzuoka, M; Suto, A1
Hattori, T; Jinushi, K; Kim, R; Kirihara, Y; Niimoto, M; Nishiyama, M; Saeki, T; Takagami, S; Toge, T1

Trials

1 trial(s) available for kt 6149 and Adenocarcinoma

ArticleYear
Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
    Anti-cancer drugs, 1995, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biotransformation; Bone Marrow Diseases; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Half-Life; Humans; Liver Neoplasms; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Unknown Primary; Salvage Therapy

1995

Other Studies

4 other study(ies) available for kt 6149 and Adenocarcinoma

ArticleYear
Reduced bone marrow toxicity of KW-2149, a mitomycin C derivative, in mice.
    Anti-cancer drugs, 1993, Volume: 4, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blood Cell Count; Bone Marrow Diseases; Colony-Forming Units Assay; Female; Hematopoietic Stem Cells; Lung Diseases; Male; Megakaryocytes; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mitomycin; Mitomycins; Organ Size; Spleen; Tumor Cells, Cultured

1993
Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
    Cancer chemotherapy and pharmacology, 1990, Volume: 27, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Colonic Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; Leukemia P388; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Nude; Mitomycin; Mitomycins; Neoplasm Transplantation

1990
Antitumor activity of 7-N-(2-((2-(gamma-L-glutamylamino) ethyl) dithio) ethyl) mitomycin C (KW2149) against human tumor xenografts serially transplanted into nude mice.
    Japanese journal of clinical oncology, 1989, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Intraductal, Noninfiltrating; Dose-Response Relationship, Drug; Humans; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred A; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Mitomycins; Neoplasm Transplantation; Random Allocation; Transplantation, Heterologous

1989
[Anticancer activities of a new mitomycin derivative KW 2149, against human tumors xenografted into nude mice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:11

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Infusions, Parenteral; Lethal Dose 50; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Mitomycins; Neoplasm Transplantation; Stomach Neoplasms

1988